Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 3Phase 2/3 1

Status

Recruiting 2Not yet recruiting 1

Sponsor Class

NIH 3NETWORK 2

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Lymphoid 1Gynecologic 1

Conditions

Neoplasms 1Endometrial Neoplasms 1Classic Follicular Lymphoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 109Radiotherapy 106Fluorouracil 76Doxorubicin 74Carboplatin 71Etoposide 67Cisplatin 67Vincristine 66Paclitaxel 58Chemotherapy, Adjuvant 53Leucovorin 47Specimen Handling 43Cytarabine 42Magnetic Resonance Spectroscopy 38Methotrexate 37Dexamethasone 33Taxes 31Bevacizumab 31Peripheral Blood Stem Cell Transplantation 30Gemcitabine 30Filgrastim 30Docetaxel 30Tamoxifen 28Melphalan 28Immunoglobulin G 25Epirubicin 25Disulfides 25Oxaliplatin 24Daunorubicin 24Prednisone 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × NIH × Hyaluronoglucosaminidase × Clear all
NCT05256225 2026-06-03

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

National Cancer Institute (NCI)

Phase 3 Recruiting
360 enrolled
Gynecologic

Neoplasms, Endometrial Neoplasms

NCT06337318 2026-05-29

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

National Cancer Institute (NCI)

Phase 3 Recruiting
600 enrolled
Lymphoid

Classic Follicular Lymphoma

NCT07388524 2026-05-13

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

National Cancer Institute (NCI)

Phase 3 Not yet recruiting
336 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡